Bicara director granted 19,475 stock options
Bicara Therapeutics Inc. director Kiran Mazumdar-Shaw received a stock option grant covering 19,475 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. director Kiran Mazumdar-Shaw received a stock option grant covering 19,475 shares of common stock. The option has an exercise price of $20.56 per share and expires on June 9, 2036.
The shares underlying this option vest on the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to her continued service on that vesting date. Following this grant, she holds 19,475 derivative securities directly.
Insider Trade Summary
Grant/Award: 19,475 shares
Grant/Award
1 txn
Insider
Mazumdar-Shaw Kiran
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,475 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,475 contracts (Direct)
Footnotes (1)
- F1. 1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.
Key Figures
Stock options granted: 19,475 options
Exercise price: $20.56 per share
Expiration date: June 9, 2036
+2 more
5 metrics
Stock options granted
19,475 options
Stock Option (Right to Buy) grant to director
Exercise price
$20.56 per share
Exercise price of stock option grant
Expiration date
June 9, 2036
Option expiration for granted stock options
Vesting date trigger
June 9, 2027
Latest vesting date or earlier next annual meeting
Derivative holdings after grant
19,475 options
Total derivative securities following transaction
Key Terms
Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "20.5600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc."
vesting financial
"shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"derivativeTransactionCount": 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bicara Therapeutics (BCAX) disclose about Kiran Mazumdar-Shaw in this Form 4?
Bicara Therapeutics reported that director Kiran Mazumdar-Shaw received a stock option grant for 19,475 shares at a $20.56 exercise price. The options are compensation-related and increase her derivative holdings to 19,475 options directly.
How many Bicara Therapeutics (BCAX) options were granted to Kiran Mazumdar-Shaw?
She was granted stock options covering 19,475 shares of Bicara Therapeutics common stock. These options give her the right to buy those shares at a fixed exercise price of $20.56 per share before the stated expiration date.
What is the exercise price and expiration date of the BCAX options granted?
The stock options have an exercise price of $20.56 per share and expire on June 9, 2036. This means she can choose to buy shares at $20.56 any time before that expiration, once the options have vested.
When do Kiran Mazumdar-Shaw’s Bicara Therapeutics (BCAX) options vest?
The options vest on the earlier of June 9, 2027 or the date of Bicara’s next Annual Meeting of Stockholders. Vesting is also conditioned on her continued service with the company through the applicable vesting date.
Is Kiran Mazumdar-Shaw’s BCAX Form 4 transaction a purchase or a grant?
The Form 4 reports a grant or award acquisition, not an open-market purchase. She received 19,475 stock options as compensation, coded as an “A” transaction, with no cash paid and a $20.56 exercise price for future share purchases.
How many Bicara Therapeutics (BCAX) derivative securities does Kiran Mazumdar-Shaw hold after this grant?
After the reported transaction, she holds 19,475 derivative securities directly. These represent stock options giving her the right to acquire an equal number of Bicara Therapeutics common shares at the fixed $20.56 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
